Stay updated on Pembrolizumab and Mifepristone in Advanced Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Mifepristone in Advanced Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab and Mifepristone in Advanced Breast Cancer Clinical Trial page
- Check6 days agoChange DetectedThe page now displays the ClinicalTrials.gov record for the terminated pembrolizumab and mifepristone breast cancer study, including its eligibility criteria, treatment plan, and outcome measures.SummaryDifference50%

- Check13 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0; the page still shows a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check27 days agoChange DetectedAn NIH-wide banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence,” and the site revision number changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check41 days agoChange DetectedThe footer revision identifier was updated from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the study content with an access-denied screen.SummaryDifference19%

- Check62 days agoChange DetectedThe page's revision label was updated to v3.7.0, replacing the previous v3.6.6, indicating a behind-the-scenes software update.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab and Mifepristone in Advanced Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Mifepristone in Advanced Breast Cancer Clinical Trial page.